Flora Peyvandi, MD, PhD

Professor of Internal Medicine; Director of the Angelo Bianchi Bonomi Hemophilia & Thrombosis Center
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

Dr. Peyvandi is Professor of Internal Medicine at the University of Milan and Director of the Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy. In addition, she participates in clinical, educational and research activities worldwide and is member of steering committees of international haemophilia societies. Her basic and medical science research focuses on the investigation of molecular mechanisms of coagulation disorders.

Presentation(s):

SS 02.1 - Welcome and Introduction
Saturday, July 9, 2022
11:30 AM – 11:35 AM
SS 02.5 - Q&A
Saturday, July 9, 2022
12:35 PM – 12:45 PM
OC 01.6 - Gene Therapy I
Saturday, July 9, 2022
1:00 PM – 2:15 PM
OC 20.2 - Artificial intelligence for the point-of-care ultrasound-based detection of joint effusion in patients with hemophilia
Sunday, July 10, 2022
11:00 AM – 11:15 AM
LB 01.1 - A Phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis
Sunday, July 10, 2022
2:45 PM – 3:00 PM
LB 01.3 - Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1
Sunday, July 10, 2022
3:15 PM – 3:30 PM
OC 27.4 - Recombinant factor VIII Fc showed better prophylactic effectiveness compared to standard half-life factor VIII in haemophilia A - results from A-SURE, a 24-month prospective, non-interventional study
Sunday, July 10, 2022
3:30 PM – 3:45 PM
PB0172 - Results of thromboelastometry and thrombin generation assays for emicizumab prophylaxis monitoring
Sunday, July 10, 2022
6:30 PM – 7:30 PM
PB0173 - Global coagulation assays in hemophilic patients on emicizumab prophylaxis, with and without partially neutralizing anti-drug antibodies
Sunday, July 10, 2022
6:30 PM – 7:30 PM
PB0176 - Gene expression profile in severe Hemophilia A patients developing anti-Factor VIII neutralizing alloantibodies
Sunday, July 10, 2022
6:30 PM – 7:30 PM
PB0212 - Collaboration between the World Federation of Hemophilia and National Registries for the Long-Term Follow-up of People with Hemophilia Treated with Gene Therapy
Sunday, July 10, 2022
6:30 PM – 7:30 PM
PB0290 - Caplacizumab for the management of acute immune-mediated thrombotic thrombocytopenic purpura: real world data from the Milan TTP Registry
Sunday, July 10, 2022
6:30 PM – 7:30 PM
PB0341 - Impact of SARS-CoV-2 Vaccination in Thrombotic Thrombocytopenic Purpura Patients
Sunday, July 10, 2022
6:30 PM – 7:30 PM
VPB0133 - Evaluation of D-dimer Concentrations Measured With Three Methods in Patients With COVID-19
Sunday, July 10, 2022
6:30 PM – 7:30 PM
VPB0227 - Laboratory monitoring in haemophilia A patients with factor VIII inhibitor treated with emicizumab
Sunday, July 10, 2022
6:30 PM – 7:30 PM
VPB0316 - Anti-ADAMTS13 IgG in congenital TTP patients
Sunday, July 10, 2022
6:30 PM – 7:30 PM
SS 18.2 - How do We Ensure a Universally Rapid and Accurate iTTP Diagnosis?
Monday, July 11, 2022
1:20 PM – 1:40 PM
SS 18.5 - Questions and Closing
Monday, July 11, 2022
2:20 PM – 2:30 PM
OC 43.3 - Clinical and phenotypic presentation of patients with low VWF in the Milan Center
Monday, July 11, 2022
3:15 PM – 3:30 PM
PB0555 - Hypoplasminogenemia: an International retroSpecTive and prOspective cohoRt studY (HISTORY): the international registry of patients with plasminogen deficiency
Monday, July 11, 2022
6:30 PM – 7:30 PM
PB0584 - Involvement of The Contact Pathway in COVID-19 Coagulopathy
Monday, July 11, 2022
6:30 PM – 7:30 PM
PB0663 - Hemophilia Joint Health Score (HJHS) and Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score in patients with hemophilia: experience from a single comprehensive care center
Monday, July 11, 2022
6:30 PM – 7:30 PM
PB0712 - The utility of bleeding assessment tools in fibrinogen deficiencies
Monday, July 11, 2022
6:30 PM – 7:30 PM
PB0806 - A screening assay for type 2B von Willebrand factor variants using an ELISA assay with ristocetin and a recombinant wild-type glycoprotein Ib.
Monday, July 11, 2022
6:30 PM – 7:30 PM
PB0821 - Data mining for profiling the mutational landscape of von Willebrand disease
Monday, July 11, 2022
6:30 PM – 7:30 PM
OC 56.5 - Insight into genetic predisposition to high plasma levels of Factor VIII (FVIII) and von Willebrand Factor (vWF) in a family with venous thrombosis.
Tuesday, July 12, 2022
11:45 AM – 12:00 PM
OC 63.3 - Safety and Efficacy of Recombinant Factor IX Fusion Protein (rIX-FP) in Previously Untreated Patients with Hemophilia B
Tuesday, July 12, 2022
3:15 PM – 3:30 PM
PB1008 - The impact of hematocrit on postoperative bleeding risk in patients undergoing robotic radical prostatectomy
Tuesday, July 12, 2022
6:30 PM – 7:30 PM
PB1125 - Musculoskeletal health and health-related quality of life in patients switching to emicizumab prophylaxis
Tuesday, July 12, 2022
6:30 PM – 7:30 PM
PB1127 - Novel accreditation of European haemophilia treatment and gene therapy centres
Tuesday, July 12, 2022
6:30 PM – 7:30 PM
PB1133 - COVID-19 vaccination in patients with hemophilia: experience from a single center
Tuesday, July 12, 2022
6:30 PM – 7:30 PM
PB1149 - Pooled analysis of long-term efficacy and safety of simoctocog alfa in previously treated patients with haemophilia A
Tuesday, July 12, 2022
6:30 PM – 7:30 PM
PB1397 - Psychological and cognitive factors involved in decision-making process of haemophilia carriers in reproductive choices
Tuesday, July 12, 2022
6:30 PM – 7:30 PM